Colorectal cancer (CRC) is one of the most common causes of cancer-related death in the world. There
is a document that angiotensin (AT) which is found to be involved in the progression of CRC. Furthermore, Angiotensin
receptor inhibitors (ARIs) and angiotensin-converting enzyme Inhibitors (ACE-Is) demonstrate activity
in CRC by their inhibition of both Insulin-like growth factor 1 (IGF-1) and Vascular endothelial growth factor
(VEGF), and therefore present a potentially novel therapeutic strategy in colorectal cancer, which have summarized
in the current review. Preclinical studies have illustrated the direct effect of major active mediator angiotensin
II (ATII) on the promotion of angiogenesis through VEGF and other proliferative mediators. Suppression
of the angiotensin II type I receptor (AT1R) via ACE-Is has shown a reduction in the development of solid tumor
and metastasis, particularly CRC incidence, polyp formation, and distant metastasis. MicroRNAs (miRs) are a
family of small nucleotides without coding that plays an important role after transcribing hundreds to thousands
of non-coding and coding gene. Against this background, the application of anti-hypertensive medications such as
losartan might have a therapeutic impact, although further preclinical and clinical studies might provide novel
insight into the potentially beneficial effect of ACE-Is in the treatment of colorectal cancer patients.
Keywords: Colorectal cancer, converting enzyme inhibitors, angiotensin receptor inhibitors, cancer-related death, proliferative mediators.
Rights & PermissionsPrintExport